Treatment
Trifluridine/tipiracil clinical trials
We’re tracking 23 recruiting studies that include Trifluridine/tipiracil, each written for real people, not researchers, below.
Recruiting studies
- NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT07270991RecruitingPhase 3
Testing a new drug combo for advanced stomach or esophageal cancer
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
AurillacAges 18 years+ - NCT06711471RecruitingPhase 2
Combination therapy for advanced stomach cancer after prior treatments
This trial tests a combination of three drugs — trifluridine/tipiracil (a chemotherapy pill), bevacizumab (avastin, a targeted therapy), and camrelizumab (an immunotherapy) — as a later treatment option for people with advanced stomach cancer who have already tried other therapies. It may help patients whose cancer has not responded to previous treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07549412RecruitingPhase 3
New chemotherapy drugs for advanced colorectal cancer
This trial tests whether a new chemotherapy combination (precemtabart tocentecan, with or without bevacizumab) works better than a standard treatment for colorectal cancer that has spread and stopped responding to previous drugs. The goal is to find treatments that help people live longer with fewer side effects.
Lone Tree, ColoradoAges 18 years+ - NCT07381764RecruitingPhase 2
Rechallenge with targeted drugs for certain colorectal cancers
This study tests a new approach for people with a specific type of metastatic colorectal cancer that has stopped responding to initial treatments. It compares reusing a targeted drug combination (irinotecan plus cetuximab) versus a different chemotherapy plus a targeted drug (trifluridine/tipiracil plus bevacizumab) to see which works better for patients whose tumors have a certain genetic profile.
AlessandriaAges 18 years+ - NCT07361003RecruitingPhase 3
Testing suvemcitug plus chemo for refractory colorectal cancer
This trial tests a new drug, suvemcitug, combined with an oral chemotherapy called FTD/TPI for people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT07146646RecruitingPhase 2
Chemo combo for advanced bile duct cancer
This trial tests a combination of two chemotherapy drugs (trifluridine/tipiracil and oxaliplatin) for people with advanced or metastatic bile duct cancer (including gallbladder cancer) who have only had one prior treatment. The goal is to see if this combination can help control the cancer.
Cleveland, OhioAges 19 years+ - NCT07085169RecruitingPhase 2
Low-dose chemo combo for advanced colorectal cancer
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
SanmingAges 60 years+ - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT05927857RecruitingPhase 1/Phase 2
Testing three medicines for advanced stomach cancer after first treatment
This study tests whether a combination of ramucirumab, nal-IRI (irinotecan liposome), and trifluridine/tipiracil can work better as a second treatment for metastatic stomach cancer. It may help people whose cancer has returned or progressed after only one prior treatment plan.
Taipei, Taiwan/TaipeiAges 20–80 - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT04660760RecruitingPhase 2
Comparing two treatments for advanced stomach cancer after first treatment
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Birmingham, AlabamaAges 18 years+ - NCT07525206RecruitingPhase 3
Combination treatment for advanced colorectal cancer
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
Goodyear, ArizonaAges 18 years+ - NCT06522919RecruitingPhase 2
Immunotherapy and chemotherapy for advanced colorectal cancer
This trial tests a sequence of treatments for people with a specific type of advanced colorectal cancer (called pMMR or MSS) that has not responded to earlier therapies. Patients first receive an immunotherapy combination (pembrolizumab plus a personalized dendritic cell vaccine) followed by a chemotherapy pill (trifluridine/tipiracil) plus bevacizumab. The goal is to see if this sequence can help control the cancer.
Meldola, Forlì CesenaAges 18 years+ - NCT07318389RecruitingEarly Phase 1
Tracking tumor resistance in metastatic colorectal cancer
This trial studies how colorectal cancer that has spread becomes resistant to treatment. By taking biopsies over time, researchers hope to find new ways to target the cancer and help patients live longer.
Houston, TexasAges 18 years+ - NCT05965531RecruitingPhase 2
TAS-102 plus radiation before surgery for rectal cancer
This trial studies whether adding TAS-102 (a chemotherapy medicine) to radiation given before treatment improves outcomes for certain locally advanced rectal cancers. It may help by trying to shrink the tumor before the next steps of care.
Guangzhou, GuangdongAges 18–70 - NCT06873763RecruitingPhase 1/Phase 2
Nelmastobart with chemo for advanced colorectal cancer
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06856837RecruitingPhase 2
Fruquintinib and Tislelizumab for advanced colorectal cancer
This trial tests a combination of two drugs, fruquintinib and tislelizumab, for people with a specific type of advanced colorectal cancer that has not spread to the liver. It is for those whose cancer is stable in certain DNA repair systems (MSS/pMMR) and who have already tried other treatments.
LinzAges 18 years+ - NCT06245356RecruitingPhase 2
A safety trial of trifluridine/tipiracil for DPD-deficient patients
This trial tests a chemotherapy drug (trifluridine/tipiracil) in people with metastatic colorectal or gastroesophageal cancer who have a DPD deficiency. DPD deficiency means your body may have trouble breaking down certain chemotherapy drugs, which can lead to serious side effects. This study aims to see if this drug is safe and effective for you.
AmiensAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Phoenix, ArizonaAges 18 years+ - NCT05438459RecruitingPhase 1/Phase 2
GAIA-102 for advanced stomach or pancreatic cancer with ascites
This trial tests a new drug, GAIA-102, given directly into the abdomen to treat advanced stomach or pancreatic cancer that has spread to the belly lining and causes fluid buildup (malignant ascites). The goal is to see if it can slow the cancer or improve symptoms.
Fukuoka, FukuokaAges 20 years+ - NCT04511039RecruitingPhase 1
New targeted pill combo for advanced colon or stomach cancers
This Phase 1 trial tests a combination of oral (swallowed) drugs—trifluridine/tipiracil plus talazoparib—in people with advanced (locally advanced or metastatic) colorectal or gastroesophageal adenocarcinoma. It’s designed to see how well the treatment can control cancer and to better understand side effects and dosing.
Buffalo, New YorkAges 18 years+
What Trifluridine/tipiracil is being studied for
Conditions with recruiting Trifluridine/tipiracil studies.
- Metastatic Colorectal Cancer
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastric Adenocarcinoma
- Colorectal cancer
- Metastatic Colorectal Cancer (CRC)
- Locally Advanced Colorectal Carcinoma
- Locally Advanced Gastroesophageal Junction Adenocarcinoma
- Metastatic Colorectal Adenocarcinoma
- Stage III Colorectal Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
Common questions
- Are there clinical trials studying Trifluridine/tipiracil?
- Yes. Clin2 currently lists 23 recruiting studies that include Trifluridine/tipiracil, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Trifluridine/tipiracil trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Trifluridine/tipiracil an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Trifluridine/tipiracil or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.